sirolimus (TAVT-18) / Tavanta Therap - LARVOL DELTA

STOP2: Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants (clinicaltrials.gov) - P1/2 | N=5 | Completed | Sponsor: Children's Hospital Medical Center, Cincinnati | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Epilepsy

6-Month Data from the Surmodics SWING First-in-Human Study to be Presented at AMP Europe (Businesswire) - "'The Sundance Sirolimus Drug-Coated Balloon represents a significant advancement in the treatment of patients with Critical lower limb ischemia and infrapopliteal arterial disease, providing a revascularization option that may lead to an improved quality of life, the reduced need for major bypass surgical intervention, and a decrease in the risk of amputation,' said Varcoe. 'I am excited to present the 6-month SWING data to an audience of my peers at AMP Europe.'"

Media quote